UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ten things you should know about protein kinases: IUPHAR Review 14

British journal of pharmacology, 2015-06, Vol.172 (11), p.2675-2700

2015

Volltextzugriff (PDF)

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Journal of medicinal chemistry, 2018-09, Vol.61 (18), p.8120-8135

2018

Volltextzugriff (PDF)

Microseed matrix screening for optimization in protein crystallization: what have we learned?

Acta crystallographica. Section F, Structural biology communications, 2014-09, Vol.70 (9), p.1117-1126

2014

Volltextzugriff (PDF)

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1

Nature (London), 2017-03, Vol.543 (7647), p.733-737

2017

Volltextzugriff (PDF)

Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches

Current topics in medicinal chemistry, 2017-01, Vol.17 (1), p.59-70

2017

Volltextzugriff (PDF)

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (11), p.4500-4505

2005

Volltextzugriff (PDF)

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer cell, 2005-02, Vol.7 (2), p.129-141

2005

Volltextzugriff (PDF)

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

Bioorganic & medicinal chemistry, 2010-10, Vol.18 (19), p.6977-6986

2010

Volltextzugriff (PDF)

Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases

Future medicinal chemistry, 2014-04, Vol.6 (5), p.541-561

2014

Volltextzugriff (PDF)

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

The Journal of biological chemistry, 2008-06, Vol.283 (26), p.18292-18302

2008

Volltextzugriff (PDF)

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Structure (London), 2005-06, Vol.13 (6), p.861-871

2005

Volltextzugriff (PDF)

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Blood, 2007-06, Vol.109 (11), p.5011-5015

2007

Volltextzugriff (PDF)

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Journal of the American Chemical Society, 2010-05, Vol.132 (20), p.7043-7048

2010

Volltextzugriff (PDF)

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

ACS medicinal chemistry letters, 2015-07, Vol.6 (7), p.776-781

2015

Volltextzugriff (PDF)

Discovery of 3-(1H-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes

Journal of medicinal chemistry, 2009-10, Vol.52 (20), p.6193-6196

2009

Volltextzugriff (PDF)

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Leukemia research, 2020-11, Vol.98, p.106458, Article 106458

2020

Volltextzugriff (PDF)

Structural biology contributions to tyrosine kinase drug discovery

Current opinion in cell biology, 2009-04, Vol.21 (2), p.280-287

2009

Volltextzugriff (PDF)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Journal of medicinal chemistry, 2010-10, Vol.53 (19), p.6934-6946

2010

Volltextzugriff (PDF)

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Acta crystallographica. Section D, Biological crystallography., 2007-01, Vol.63 (1), p.80-93

2007

Volltextzugriff (PDF)

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug

Journal of medicinal chemistry, 2022-06, Vol.65 (11), p.7581-7594

2022

Volltextzugriff (PDF)

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

Nature reviews. Cancer, 2007-05, Vol.7 (5), p.345-356

2007

Volltextzugriff (PDF)

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

Future medicinal chemistry, 2014-04, Vol.6 (5), p.541

2014

Volltextzugriff (PDF)

Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”

Angewandte Chemie International Edition, 2022-11, Vol.61 (46), p.e202117276-n/a

International ed. in English, 2022

Volltextzugriff (PDF)

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors

Nature (London), 2010-01, Vol.463 (7280), p.501-506

2010

Volltextzugriff (PDF)

Type II Inhibitors Targeting CDK2

ACS chemical biology, 2015-09, Vol.10 (9), p.2116-2125

2015

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(53)
Humans
(43)
Models, Molecular
(22)
Biological And Medical Sciences
(21)
Animals
(20)
Pharmacology & Pharmacy
(17)
Physical Sciences
(17)
Binding Sites
(16)
Biochemistry & Molecular Biology
(16)
Chemistry, Medicinal
(15)
Medical Sciences
(15)
Pyrimidines - Pharmacology
(14)
Benzamides
(13)
Chemistry
(13)
Imatinib Mesylate
(13)
Mice
(13)
Protein Kinase Inhibitors - Chemistry
(13)
Protein Kinase Inhibitors - Pharmacology
(13)
Amino Acid Sequence
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ten things you should know about protein kinases: IUPHAR Review 14

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Microseed matrix screening for optimization in protein crystallization: what have we learned?

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1

Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Discovery of 3-(1H-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Structural biology contributions to tyrosine kinase drug discovery

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors

Type II Inhibitors Targeting CDK2

Suchergebnisse filtern